Table 1 Baseline characteristics in the modified intention to treat (mITT) population
|  | Azithromycin (n = 32) | Placebo (n = 31) |  |
|---|---|---|---|
Age at inclusion (median, range) | 59 (19–80) | 62 (30–82) | p = 0.382 |
Gender | Â | Â | |
Male | 20 (62.5%) | 19 (61.3%) | p = 1.000 |
Female | 12 (37.5%) | 12 (38.7%) | |
ECOG at randomization | Â | Â | Â |
0 | 31 (96.9%) | 28 (90.3%) | p = 0.355 |
1 | 1 (3.1%) | 3 (9.7%) | |
Tumor entity | Â | Â | Â |
Colorectal cancer | 7 (21.9%) | 2 (6.5%) | p = 0.266 |
Lung cancer | 6 (18.8%) | 6 (19.4%) | |
Pancreatic cancer | 5 (15.6%) | 5 (16.1%) | |
Sarcoma | 5 (15.6%) | 2 (6.5%) | |
Extranodal lymphoma | 2 (6.3%) | 2 (6.5%) | |
Gastric cancer | 1 (3.1%) | 2 (6.5%) | |
Cholangiocellular carcinoma | 1 (3.1%) | 1 (3.2%) | |
Breast cancer | 1 (3.1%) | 6 (19.4%) | |
Neuroendocrine carcinoma | 0 (0.0%) | 3 (9.7%) | |
Other | 4 (12.5%) | 2 (6.5%) | |
Ongoing treatment | Â | Â | Â |
Chemotherapy | 17 (53.1%) | 17 (54.8%) | p = 0.539 |
Targeted therapy | 2 (6.3%) | 1 (3.2%) | |
Immune checkpoint inhibition (ICI) | 4 (12.5%) | 3 (9.7%) | |
Chemotherapy + targeted therapy | 9 (28.1%) | 7 (22.6%) | |
Chemotherapy + ICI | 0 (0.0%) | 3 (9.7%) |